Eagle Pharmaceuticals, Inc. (EGRX): Price and Financial Metrics


Eagle Pharmaceuticals, Inc. (EGRX): $32.72

-1.04 (-3.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EGRX POWR Grades

  • Value is the dimension where EGRX ranks best; there it ranks ahead of 98.5% of US stocks.
  • The strongest trend for EGRX is in Stability, which has been heading down over the past 177 days.
  • EGRX's current lowest rank is in the Stability metric (where it is better than 3.64% of US stocks).

EGRX Stock Summary

  • With a year-over-year growth in debt of 123.33%, EAGLE PHARMACEUTICALS INC's debt growth rate surpasses 89.88% of about US stocks.
  • Over the past twelve months, EGRX has reported earnings growth of 612.89%, putting it ahead of 97.18% of US stocks in our set.
  • Revenue growth over the past 12 months for EAGLE PHARMACEUTICALS INC comes in at 66.48%, a number that bests 86.95% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EAGLE PHARMACEUTICALS INC are WEAV, RCEL, APDN, BIOC, and VBIV.
  • EGRX's SEC filings can be seen here. And to visit EAGLE PHARMACEUTICALS INC's official web site, go to www.eagleus.com.

EGRX Valuation Summary

  • In comparison to the median Healthcare stock, EGRX's price/sales ratio is 20% lower, now standing at 1.6.
  • EGRX's price/sales ratio has moved down 8.5 over the prior 107 months.

Below are key valuation metrics over time for EGRX.

Stock Date P/S P/B P/E EV/EBIT
EGRX 2022-12-02 1.6 2 22.0 9.9
EGRX 2022-12-01 1.5 2 21.7 9.8
EGRX 2022-11-30 1.6 2 22.2 10.0
EGRX 2022-11-29 1.5 2 21.6 9.7
EGRX 2022-11-28 1.6 2 21.8 9.9
EGRX 2022-11-25 1.6 2 21.9 9.9

EGRX Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -96.97%.
  • The 2 year net cashflow from operations growth rate now stands at -96.57%.
  • The 5 year revenue growth rate now stands at 1.4%.
EGRX's revenue has moved up $82,503,000 over the prior 52 months.

The table below shows EGRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 298.231 21.225 21.281
2022-06-30 272.183 35.529 22.79
2022-03-31 246.171 1.13 35.852
2021-12-31 171.546 28.219 -8.627
2021-09-30 179.142 39.898 5.626
2021-06-30 189.217 44.458 18.307

EGRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EGRX has a Quality Grade of B, ranking ahead of 92.42% of graded US stocks.
  • EGRX's asset turnover comes in at 0.738 -- ranking 36th of 682 Pharmaceutical Products stocks.
  • ACUR, XENE, and KMPH are the stocks whose asset turnover ratios are most correlated with EGRX.

The table below shows EGRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.738 0.756 0.315
2021-03-31 0.719 0.735 0.316
2020-12-31 0.671 0.758 0.264
2020-09-30 0.664 0.761 0.184
2020-06-30 0.628 0.732 0.068
2020-03-31 0.677 0.711 0.109

EGRX Price Target

For more insight on analysts targets of EGRX, see our EGRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $48.50 Average Broker Recommendation 1.67 (Moderate Buy)

EGRX Stock Price Chart Interactive Chart >

Price chart for EGRX

EGRX Price/Volume Stats

Current price $32.72 52-week high $56.43
Prev. close $33.76 52-week low $24.35
Day low $32.62 Volume 70,691
Day high $34.29 Avg. volume 143,641
50-day MA $32.21 Dividend yield N/A
200-day MA $40.17 Market Cap 425.88M

Eagle Pharmaceuticals, Inc. (EGRX) Company Bio


Eagle Pharmaceuticals focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company was founded in 2007 and is based in Woodcliff Lake, New Jersey.


EGRX Latest News Stream


Event/Time News Detail
Loading, please wait...

EGRX Latest Social Stream


Loading social stream, please wait...

View Full EGRX Social Stream

Latest EGRX News From Around the Web

Below are the latest news stories about EAGLE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EGRX as an investment opportunity.

Eagle Pharmaceuticals’ Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York Palace

KOL headshot KOL headshot KOL headshot KOL headshot KOL headshot KOL headshot -- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline programs: Enalare’s ENA-001, CAL02, BARHEMSYS®, BYFAVO® and landiolol -- WOODCLIFF LAKE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Ea

Yahoo | December 1, 2022

Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline programs: Enalare’s ENA-001, CAL02, BARHEMSYS®, BYFAVO® and landiolol -- WOODCLIFF LAKE, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today anno

Yahoo | November 16, 2022

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early as the beginning of 2023 -- -- CAL02 is being developed as an adjunct to the clinically indicated antibiotic treatment -- WOODCLIFF LAKE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administra

Yahoo | November 14, 2022

Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results

WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain line items in the financial statements included therein and corresponding references to such items in the narrative disclosure as described in the Company's Form 8-K/A filed on November 9, 2022. All other info

Yahoo | November 9, 2022

Industry Analysts Just Made A Substantial Upgrade To Their Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Revenue Forecasts

Shareholders in Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) may be thrilled to learn that the analysts have just...

Yahoo | November 9, 2022

Read More 'EGRX' Stories Here

EGRX Price Returns

1-mo -17.64%
3-mo 5.92%
6-mo -25.91%
1-year -31.29%
3-year -42.02%
5-year -43.74%
YTD -35.74%
2021 9.34%
2020 -22.49%
2019 49.12%
2018 -24.58%
2017 -32.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8451 seconds.